Therefore, additional studies of the role of SHIP2 in CRC are warranted, as this could provide alternative ways to approach inhibition of the PI3K/AKT axis as a means of treatment for a subset of colon cancer tumors. The gene discussed is INPPL1; the disease is malignant colon neoplasm.